OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology Communications is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population	120
Pain in chronic liver disease compared to other chronic conditions: Results from a contemporary nationally representative cohort study	116
Issue Information	110
Erratum: Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study	82
Increasing nonalcoholic fatty liver disease–related mortality rates in the United States from 1999 to 2022	74
Copper deficiency is an independent risk factor for mortality in patients with advanced liver disease	70
A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis	65
Medical malpractice claims in Hepatology: Rates, Reasons, and Results	63
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials	63
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database	63
Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas	63
Visualizing in situ viral replication across the natural history of chronic HBV infection	58
Targeting hepatocyte-specific SLC2A8 blocks hepatic steatosis and dissociates TCA cycle flux inhibition from glutamine anaplerosis	56
HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells	55
Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency	53
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda	52
Pharmacist‐led educational interventions involving the “hidden” patient in cirrhosis—Caregivers	52
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease	52
Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis	51
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia	49
Zinc fingers and homeoboxes 2 is required for diethylnitrosamine‐induced liver tumor formation in C57BL/6 mice	49
Development and evaluation of a virtual reality driving test for patients with cirrhosis	49
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?	47
A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer	44
Aramchol attenuates fibrosis in mouse models of biliary fibrosis and blocks the TGFβ-induced fibroinflammatory mediators in cholangiocytes	44

Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease	43
Co‐regulation of hepatic steatosis by ferritinophagy and unsaturated fatty acid supply	41
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants	41
Depression and anxiety management in cirrhosis	40
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)	40
Association between widespread pain and associated symptoms in patients with cirrhosis	40
Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease	39
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial	39
Granulomatous liver diseases	38
Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease	38
Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages	36
Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH	36